Read by QxMD icon Read


shared collection
13 papers 0 to 25 followers Technical
By May Xu Technical womnn
Song Xue, Ying-Xia Chen, Shu-Kui Qin, Ai-Zhen Yang, Lin Wang, Hai-Jun Xu, Hai-Yun Geng
Raltitrexed is a specific inhibitor of thymidylate synthase (TS), which has been considered as a potential chemotherapeutic agent for the treatment of advanced gastric cancer. In the present study, the apoptosis mechanisms of raltitrexed in SGC7901 human gastric cancer cells were investigated. The cytotoxic activity of raltitrexed on SGC7901 cells was determined by cell counting kit-8 (CCK-8) assay. The CCK‑8 assay indicated that raltitrexed inhibits SGC7901 cell growth in a dose- and time-dependent manner...
October 2014: Molecular Medicine Reports
Sandro Barni, Antonio Ghidini, Andrea Coinu, Karen Borgonovo, Fausto Petrelli
Raltitrexed is a thymidylate synthase inhibitor belonging to the antimetabolite class of cytotoxic drugs. It is also effective in colorectal cancer (CRC) both as a single agent and in combination with other drugs, in particular in those patients with cardiologic risk factors or previous cardiotoxicity. The efficacy of first-line raltitrexed-based chemotherapy containing oxaliplatin (TOMOX) and irinotecan (TOMIRI) was investigated in this systematic review. Studies that enrolled advanced CRC patients for first-line therapy with TOMOX/TOMIRI combinations were identified using electronic databases (Pubmed, SCOPUS, Web of Science, EMBASE, and the Cochrane Library)...
November 2014: Anti-cancer Drugs
Faisal A Siddiqui, Katelyn M Atkins, Brian S Diggs, Charles R Thomas, John G Hunter, James P Dolan
BACKGROUND: Patients treated with neoadjuvant chemoradiotherapy (NAC) followed by esophagectomy are more likely to have negative margins at resection, be downstaged, and have improved overall survival (OS). The specific aim of this study was to analyze OS outcomes using NAC followed by esophagectomy at a single, tertiary care academic medical center. METHODS: We retrospectively analyzed 106 patients that underwent NAC with platinum-based chemotherapy plus 5-fluorouracil (5-FU) or capecitabine followed by esophagectomy from September 1996 to May 2011...
April 2014: Journal of Gastrointestinal Oncology
Jae Hyun Kim, Pyoung Rak Choi, Seun Ja Park, Moo In Park, Won Moon, Sung Eun Kim, Gyu Won Lee
BACKGROUND/AIMS: Information on prognostic factors for metastatic colorectal cancer is an important basis for planning the treatment and predicting the outcomes of the patients; however, it has not been well established. The aim of this study was to identify factors that predict results of chemotherapy and to establish a plan for treatment of patients whose tumors are inoperable due to metastatic colorectal cancer. METHODS: We conducted a retrospective review of records from 75 patients treated for colorectal cancer in Kosin University Gospel Hospital, from October 2004 to September 2008...
April 2014: Korean Journal of Gastroenterology, Taehan Sohwagi Hakhoe Chi
Hiroshi Soeda, Hideki Shimodaira, Mika Watanabe, Takao Suzuki, Makio Gamo, Masanobu Takahashi, Keigo Komine, Shunsuke Kato, Chikashi Ishioka
Fluoropyrimidine-based chemotherapy plus antibody therapy is currently the standard first-line treatment for metastatic colorectal cancer (mCRC). In this study, we investigated the hypothesis that mutations in several of the targeted oncogenes are correlated with treatment outcomes in mCRC patients receiving different first-line regimens. Our study included a total of 194 patients who had undergone various forms of first-line chemotherapy. The KRAS, BRAF, PIK3CA, NRAS and AKT1 mutational status of the tumors was assessed and the association between mutational status and treatment outcome was evaluated...
May 2014: Molecular and Clinical Oncology
Michio Kimura, Eiseki Usami, Tetsufumi Kanematsu, Mina Iwai, Tomoaki Yoshimura, Hiromi Mori, Tadashi Sugiyama, Hitomi Teramachi
In the treatment of advanced or recurrent gastric cancer, the prolongation of survival depends on the use of second-line therapy, with paclitaxel (PTX) or irinotecan (CPT-11) as the key agents. The present study aimed to retrospectively investigate the safety and continuity of weekly PTX and CPT-11 monotherapy as second- or third-line treatment for advanced or recurrent gastric cancer. A total of 62 patients who had received PTX or CPT-11 for gastric cancer at the Ogaki Municipal Hospital (Ogaki, Japan) were retrospectively reviewed...
May 2014: Molecular and Clinical Oncology
Peter M Wilson, Peter V Danenberg, Patrick G Johnston, Heinz-Josef Lenz, Robert D Ladner
Over the past 60 years, chemotherapeutic agents that target thymidylate biosynthesis and the enzyme thymidylate synthase (TS) have remained among the most-successful drugs used in the treatment of cancer. Fluoropyrimidines, such as 5-fluorouracil and capecitabine, and antifolates, such as methotrexate and pemetrexed, induce a state of thymidylate deficiency and imbalances in the nucleotide pool that impair DNA replication and repair. TS-targeted agents are used to treat numerous solid and haematological malignancies, either alone or as foundational therapeutics in combination treatment regimens...
May 2014: Nature Reviews. Clinical Oncology
M M Dias, J-P Pignon, C S Karapetis, V Boige, B Glimelius, D M Kweekel, P N Lara, P Laurent-Puig, E Martinez-Balibrea, D Páez, C J A Punt, M W Redman, G Toffoli, M Wadelius, R A McKinnon, M J Sorich
To date, studies of irinotecan pharmacogenetics have mostly focused on the effect of the UGT1A1*28 allele on irinotecan-related toxicity. However, the clinical utility of routine UGT1A1*28 genotyping to pre-emptively adjust irinotecan dosage is dependent upon whether UGT1A1*28 also affects patient survival following irinotecan therapy. Previous observational studies evaluating the influence of UGT1A1*28 on survival have shown contradictory results. A systematic review and meta-analysis of both published and unpublished data were performed to summarize the available evidence of the relationship between the UGT1A1*28 allele and patient survival related to irinotecan therapy...
October 2014: Pharmacogenomics Journal
Thomas Melchardt, Teresa Magnes, Lukas Weiss, Michael Grundbichler, Michael Strasser, Clemens Hufnagl, Martin Moik, Richard Greil, Alexander Egle
BACKGROUND: Complementary and alternative medicine is often used by patients with malignant glioma. Although several interactions of various alternative agents with chemotherapy are known, none has been described for temozolomide so far. CASE PRESENTATION: We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma. After cessation of the herbal formula as well as the chemotherapy liver enzymes slowly normalized...
March 30, 2014: BMC Complementary and Alternative Medicine
Christopher L Wolfgang, Joseph M Herman, Daniel A Laheru, Alison P Klein, Michael A Erdek, Elliot K Fishman, Ralph H Hruban
Pancreatic cancer is currently one of the deadliest of the solid malignancies. However, surgery to resect neoplasms of the pancreas is safer and less invasive than ever, novel drug combinations have been shown to improve survival, advances in radiation therapy have resulted in less toxicity, and enormous strides have been made in the understanding of the fundamental genetics of pancreatic cancer. These advances provide hope but they also increase the complexity of caring for patients. It is clear that multidisciplinary care that provides comprehensive and coordinated evaluation and treatment is the most effective way to manage patients with pancreatic cancer...
September 2013: CA: a Cancer Journal for Clinicians
Y Liu, W Wu, W Hong, X Sun, J Wu, Q Huang
AIMS: To evaluate the efficiency and safety profile of raltitrexed-based chemotherapy in the treatment of advanced colorectal cancer. METHODS: An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer. The outcomes included overall survival, overall response rate and toxicities. RESULTS: This meta-analysis included 11 studies with 4622 patients...
April 2014: Clinics and Research in Hepatology and Gastroenterology
Ke Cheng, Ye Chen, Long-Hao Li, Ji-Yan Liu
No standard chemotherapy regimen has been established for metastatic colorectal cancer (mCRC) after progression on 5-fluorouracil, oxaliplatin, and irinotecan. Here, we report the combination of raltitrexed and bevacizumab as a salvage regimen for the treatment of three heavily pretreated patients with KRAS mutant mCRC. All three patients had stable disease (SD) according to response evaluation criteria in solid tumors (RECIST) criteria, progression free survival (PFS) were 3.0, 3.2 months for the first two patients and have not been reached for over 5 months for the third patient and no severe adverse effect was observed...
October 2013: Journal of Cancer Research and Therapeutics
Oktay Bozkurt, Halit Karaca, Aydin Ciltas, M Ali Kaplan, Mustafa Benekli, Alper Sevinc, Umut Demirci, Tulay Eren, Hilmi Kodaz, Abdurrahman Isikdogan, Metin Ozkan, Suleyman Buyukberber
BACKGROUND: There is no standard treatment for patients with colorectal cancer (CRC) progressing after irinotecan and oxaliplatin treatment. Here we aimed to retrospectively evaluate the efficacy and tolerability of raltitrexed in combination with oral 5-fluoropyrimidine (uracil tegafur-UFT) or mitomycin C as salvage therapy in mCRC patients. MATERIALS AND METHODS: A total of 62 patients who had received raltitrexed combined with UFT or mitomycin C were identified between December 2008 and June 2013...
2014: Asian Pacific Journal of Cancer Prevention: APJCP
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"